Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 18/20 | 0.68 |
| ▸ | OPRM1 | P35372 | 13/20 | 0.67 |
| ▸ | OPRK1 | P41145 | 4/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4357610 | 0.82 | OPRL1 (0.70) | OPRL1OPRM1OPRK1 | |
| SCHEMBL11244959 | 0.81 | SLC6A3 (0.47) | OPRL1OPRM1OPRK1 | |
| SCHEMBL3413521 | 0.81 | OPRL1 (1.00) | OPRL1OPRM1OPRK1 | |
| SCHEMBL317530 | 0.81 | OPRL1 (1.00) | OPRL1OPRM1OPRK1 | |
| SCHEMBL4352504 | 0.81 | OPRL1 (0.68) | OPRL1OPRM1OPRK1 | |
| SCHEMBL3144048 | 0.80 | OPRL1 (0.62) | OPRL1OPRM1OPRK1 | |
| SCHEMBL5156523 | 0.80 | OPRL1 (0.62) | OPRL1OPRM1OPRK1 | |
| SCHEMBL11466330 | 0.80 | SLC18A3 (0.46) | OPRL1OPRM1OPRK1 | |
| SCHEMBL11831180 | 0.80 | SLC18A3 (0.46) | OPRL1OPRM1OPRK1 | |
| SCHEMBL11823390 | 0.80 | SLC18A3 (0.46) | OPRL1OPRM1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020120606-A1 | NEW PYRROLIDINE-2-CARBOXYLIC ACID DERIVATIVES FOR TREATING PAIN AND PAIN RELATED CONDITIONS | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2020-06-18 | — | — | WO | disclosed |
| EP-2649044-B1 | METHOD FOR SYNTHESISING SUBSTITUTED AMINOCYCLOHEXANONE DERIVATIVES | GRUENENTHAL GMBH (DE) | 2017-09-20 | — | — | EP | disclosed |
| EP-1487778-B1 | SUBSTITUTED 4-AMINOCYCLOHEXANOLS | GRUENENTHAL GMBH (DE) | 2012-07-11 | — | — | EP | disclosed |
| US-7211694-B2 | Substituted 4-aminocyclohexanols | GRUENENTHAL GMBH (DE) | 2007-05-01 | — | — | US | disclosed |
| US-20050187220-A1 | Substituted 4-aminocyclohexanols | GRUENENTHAL GMBH (DE) | 2005-08-25 | — | — | US | disclosed |
| EP-1487778-A1 | SUBSTITUTED 4-AMINOCYCLOHEXANOLS | Grünenthal GmbH (DE) | 2004-12-22 | — | — | EP | disclosed |
| WO-2003080557-A1 | SUBSTITUTED 4-AMINOCYCLOHEXANOLS | Grünenthal GmbH (DE) | 2003-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050187220-A1 | Substituted 4-aminocyclohexanols | ADRA2C, OPRK1, OPRD1 | OPRL1 4/4885OPRM1 6/4885OPRK1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.